AQP4 and neuromyelitis optica: Background and aims: Little is known about the impact of myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) and aquaporin‐4‐IgG‐seropositive neuromyelitis optica spectrum disorder (NMOSD‐AQP4+) on cognitive performance (CP).